October 1, 2026
Dr. Teresa Sanchez has received a new R01 grant from the National Institute of Neurological Disorders and Stroke (NINDS) to investigate how sepsis and systemic inflammation contribute to cerebrovascular dysfunction and cognitive decline. The project, entitled “Endothelial Sphingolipid Signaling in Cerebrovascular Inflammation and Cognitive Decline: Mechanisms and Therapeutic Potential,” will define the molecular and cellular mechanisms linking systemic inflammation to brain dysfunction and evaluate novel therapeutic strategies to protect the cerebral vasculature, preserve cognitive function,...
September 30, 2026
After an extraordinary 30 years at Weill Cornell Medicine, Dr. Selina Chen-Kiang will transition from her role as Full Tenured Professor of Pathology and Laboratory Medicine to Professor Emerita. This well-deserved appointment honors a distinguished career shaped by scientific originality, translational impact, exceptional mentorship, and dedicated service to Weill Cornell Medicine and the broader cancer and immunology communities.
September 15, 2026
The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of interferon-alpha can induce significant side effects, developing new focused strategies based on these mechanistic findings could meet an important need in cancer therapy.
September 11, 2026
Read the latest WCM Pathology Newsletter to learn more about our innovations, educational accomplishments, faculty updates and much more. You can also read our past issues here.
September 7, 2026
Researchers at Weill Cornell Medicine and Hospital for Special Surgery have discovered the stem cells—unspecialized cells that can develop into specific cell types—that give rise to the body’s tendons and ligaments, the tissues connecting muscles and bones. They also found that when these stem cells become hyperactive in the lower spine, they contribute to lumbar spinal stenosis. This condition, which impacts an estimated 103 million people worldwide, involves enlarged ligaments that can narrow the spinal canal and compress nerves, causing pain, numbness and difficulty walking.
August 17, 2026
Residency applicants for 2027 — we’d love to meet you! Join us for a Virtual Open House on August 27 from 4–5 PM EST to learn more about us & meet our team. Register here!
August 10, 2026
A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. The discovery points to a possible solution to the problem of BTK inhibitor treatment resistance.BTK inhibitors reduce the activity of the enzyme BTK (Bruton’s Tyrosine Kinase), which has a central role in immune cells called B cells. Inhibiting BTK chokes off the ability of B cells to proliferate, which has benefits against some blood cancers including several types of lymphoma...
July 20, 2026
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. The advances represent progress in precision medicine and point to the more routine use of tumor organoids as models for evaluating and optimizing cancer treatments.
July 20, 2026
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.
July 17, 2026
Welcome to our new Pathology House Staff and Fellows for the 2026-2027 academic year!